Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific…
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, announced that it will present new preclinical data on TFG-001 at the 7th…
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO)…
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026 SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, announced that the company and key collaborators…
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis Baszucki Group announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic…
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as the first TROP2-directed antibody-drug conjugate for first-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for…
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Bristol Myers Squibb announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society…
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality…
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of…
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases,…
Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes Flatiron Health announced the launch of Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study…